C-reactive Protein Testing Market Size & Growth Forecast 2027–2036, By Segments (Detection Range, Assay Type, End Use, Disease Area), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
C-reactive Protein Testing Market size was over USD 5.4 billion in 2026 and is likely to grow at a 1.62% CAGR between 2027 and 2036, crossing USD 6.34 billion by 2036. The industry revenue for 2027 is estimated at USD 5.47 billion.
Get more details on this report
Request Free Sample ReportC-reactive Protein Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America held 43.31% of the market in 2026, supported by established laboratory infrastructure, high routine testing volumes, and widespread CRP use across hospitals, laboratories, and physician offices.
- Asia Pacific is projected to grow at a 4.9% CAGR, fueled by expanding diagnostic access, rising hospital and decentralized testing demand, and greater use of cost-effective CRP testing for infection assessment and triage.
Segment Momentum
- hs-CRP held a 60.16% share in 2026 because it supports sensitive measurement of low-grade inflammation for routine risk assessment and ongoing patient monitoring.
- ELISA is the fastest-growing assay type as laboratories increasingly value its flexibility for batch testing and broader analytical applications beyond routine automated workflows.
Market Expansion Drivers
- Rising prevalence of chronic inflammatory and cardiovascular diseases driving CRP demand.
- Expansion of point-of-care CRP testing enabling rapid clinical decision-making.
- Growth of preventive screening programs in primary healthcare systems.
Leading Market Participants
- Top companies in the C-reactive protein testing market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (USA), Siemens Healthineers AG (Germany), Danaher Corporation (USA), Thermo Fisher Scientific Inc. (USA), Quest Diagnostics Incorporated (USA), Laboratory Corporation of America Holdings (USA), HORIBA, Ltd. (Japan), Randox Laboratories Ltd. (United Kingdom), Boditech Med Inc. (South Korea).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 5.4 billion
- 2027 Estimated Market Size: USD 5.47 billion.
- Projected Market Size: USD 6.34 billion by 2036
- Growth Forecast: 1.62% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: hs-CRP (Detection Range) | Immunoturbidimetric Assay (Assay Type) | Hospitals (End Use) | Rheumatoid Arthritis (Disease Area)
- Emerging Opportunity Segment: Conventional CRP (Detection Range) | ELISA (Assay Type) | Laboratories (End Use) | Cardiovascular Diseases (Disease Area)
Market Growth Drivers and Industry Trends
Rising prevalence of chronic inflammatory and cardiovascular diseases driving CRP demand
Increasing prevalence of chronic inflammatory and cardiovascular diseases is supporting C-reactive protein testing market growth by strengthening the need for CRP assessment in clinical evaluation. As healthcare providers manage conditions associated with inflammation, demand for testing that assists in evaluating inflammatory activity becomes more relevant across diagnostic and patient-monitoring workflows.
Expansion of point-of-care CRP testing enabling rapid clinical decision-making
Point-of-care testing expansion is accelerating C-reactive protein testing market demand by bringing rapid CRP assessment closer to clinical decision points. The availability of testing at the point of care can help healthcare professionals obtain results without relying solely on centralized laboratory workflows, supporting faster evaluation and more immediate treatment-related decisions.
Growth of preventive screening programs in primary healthcare systems
The expansion of preventive screening initiatives within primary healthcare systems is creating additional opportunities for the C-reactive protein testing market as routine health assessments increasingly incorporate diagnostic evaluation. Broader screening activity can increase the use of CRP testing in primary-care settings, particularly where healthcare providers seek information that supports earlier assessment of inflammatory conditions.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of chronic inflammatory and cardiovascular diseases driving CRP demand | 2.00% | High | North America, Europe | High | Near Term |
| Expansion of point-of-care CRP testing enabling rapid clinical decision-making | 1.80% | High | North America, Asia Pacific | High | Near Term |
| Growth of preventive screening programs in primary healthcare systems | 1.70% | High | Europe, Asia Pacific | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the C-reactive protein testing market, North America held the largest share of 43.31% in 2026, reflecting advanced clinical laboratory infrastructure, strong adoption of diagnostic testing, and heightened emphasis on rapid assessment of inflammation and infection. Healthcare providers increasingly rely on C-reactive protein testing to support clinical decision-making across infectious diseases, inflammatory conditions, cardiovascular care, and other diagnostic applications. The region's established healthcare systems facilitate the integration of laboratory and point-of-care testing into routine care pathways. Continued investment in diagnostic technologies, growing preference for faster clinical assessment, and increasing focus on personalized and evidence-based treatment approaches further support regional market strength.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is the fastest-growing regional market, supported by expanding healthcare infrastructure, increasing diagnostic awareness, and rising demand for accessible testing across both hospitals and outpatient settings. Improvements in clinical laboratories and point-of-care diagnostic capabilities are broadening access to inflammatory biomarker testing, particularly as healthcare systems continue to modernize. Growing patient volumes and increasing emphasis on early disease detection are encouraging wider use of C-reactive protein assessment. Public and private healthcare investments, together with greater adoption of automated diagnostic platforms, are strengthening the region's capacity to incorporate these tests into routine clinical workflows.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Decision SupportGermany is emphasizing C-reactive protein testing as part of evidence-based diagnostic pathways for inflammatory and infectious diseases. Laboratories and outpatient providers are adopting standardized testing approaches that improve treatment decisions and patient monitoring.
France 🇫🇷
Primary Care DiagnosticsFrance is promoting broader use of C-reactive protein testing in primary care to support more targeted prescribing practices. Demand is centered on accessible diagnostic solutions that help physicians distinguish bacterial from viral infections and optimize treatment pathways.
Italy 🇮🇹
Laboratory ModernizationItaly is investing in modern laboratory capabilities that incorporate C-reactive protein testing into routine inflammatory disease assessment. Hospitals are prioritizing efficient testing platforms that can handle growing demand for diagnostic monitoring services.
Japan 🇯🇵
Preventive Diagnostics FocusJapan is integrating C-reactive protein testing into preventive health programs and routine clinical evaluations. The country's aging population is driving demand for reliable biomarkers that aid in early detection of inflammation-related conditions and ongoing disease management.
South Korea 🇰🇷
Rapid Testing IntegrationSouth Korea is increasing the adoption of rapid C-reactive protein assays in hospitals and clinics seeking faster diagnostic turnaround. Healthcare providers are focusing on technologies that improve patient triage and support efficient management of infectious diseases.
United States 🇺🇸
Point-of-Care ExpansionThe U.S. is expanding the use of C-reactive protein testing across emergency care, primary care, and chronic disease management settings. Healthcare providers are prioritizing rapid diagnostic tools that support timely infection assessment and reduce unnecessary antibiotic prescribing.
Segment Leadership and Growth Trends
C-reactive Protein Testing Market Share (%), by Detection Range, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportDetection Range Segment Analysis: hs-CRP (Largest Segment) vs Conventional CRP (Fastest-Growing Segment)
The hs-CRP segment held the largest share of the C-reactive protein testing market at 60.16% in 2026, driven by its ability to detect low levels of C-reactive protein and support more sensitive assessment of inflammatory conditions. Its clinical relevance in evaluating cardiovascular risk and identifying subtle inflammatory changes has increased demand for high-sensitivity testing. Growing emphasis on preventive healthcare and early risk assessment is further supporting the use of hs-CRP testing across diagnostic settings.
Conventional CRP is experiencing strong growth as healthcare systems continue to rely on established inflammatory testing for routine clinical evaluation. The test provides useful support for assessing inflammation and monitoring conditions where changes in inflammatory status can guide clinical decisions. Its established role, broad diagnostic applicability, and continued need for accessible inflammatory assessment are contributing to sustained adoption across healthcare facilities.
Assay Type Segment Analysis: Immunoturbidimetric Assay (Largest Segment) vs ELISA (Fastest-Growing Segment)
Immunoturbidimetric assay accounted for the largest share of the C-reactive protein testing market at 51.37% in 2026, supported by its suitability for routine laboratory testing and compatibility with automated diagnostic workflows. The assay enables efficient measurement of C-reactive protein and can be incorporated into established clinical chemistry systems, supporting consistent testing across healthcare facilities. Its operational convenience, established laboratory use, and ability to support high-throughput diagnostic processes continue to reinforce its market position.
ELISA is gaining momentum as demand rises for sensitive and reliable laboratory-based detection methods across clinical and research applications. Its established immunoassay principle enables targeted measurement through specific antigen-antibody interactions, supporting accurate analytical performance. Increasing interest in advanced diagnostic techniques and expanding laboratory capabilities are encouraging greater use of ELISA-based approaches for C-reactive protein assessment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Detection Range | hs-CRP, Conventional CRP, cCRP | hs-CRP | Conventional CRP |
| Assay Type | Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others | Immunoturbidimetric Assay | ELISA |
| End Use | Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home, Others | Hospitals | Laboratories |
| Disease Area | Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others | Rheumatoid Arthritis | Cardiovascular Diseases |
Competitive Landscape and Market Positioning
Leading companies in the C-reactive protein testing market:
1. F. Hoffmann-La Roche Ltd. (Switzerland)
2. Abbott Laboratories (USA)
3. Siemens Healthineers AG (Germany)
4. Danaher Corporation (USA)
5. Thermo Fisher Scientific Inc. (USA)
6. Quest Diagnostics Incorporated (USA)
7. Laboratory Corporation of America Holdings (USA)
8. HORIBA Ltd. (Japan)
9. Randox Laboratories Ltd. (United Kingdom)
10. Boditech Med Inc. (South Korea)
Growing demand for rapid inflammatory biomarker assessment is advancing the C-reactive protein testing market, with manufacturers introducing high-sensitivity assays, point-of-care testing solutions, and automated diagnostic platforms that improve testing efficiency and clinical decision-making.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| F. Hoffmann-La Roche Ltd. (Switzerland) | |||||||
| Abbott Laboratories (USA) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Danaher Corporation (USA) | |||||||
| Thermo Fisher Scientific Inc. (USA) | |||||||
| Quest Diagnostics Incorporated (USA) | |||||||
| Laboratory Corporation of America Holdings (USA) | |||||||
| HORIBA Ltd. (Japan) | |||||||
| Randox Laboratories Ltd. (United Kingdom) | |||||||
| Boditech Med Inc. (South Korea). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| HORIBA | Sep-25 | HORIBA entered a strategic partnership with GeodAIsics to develop an AI-enabled solution for early sepsis detection. The collaboration integrates hematology analyzers, including CRP-capable systems, to identify infection and inflammation patterns, strengthening diagnostic decision support and expanding the clinical utility of CRP-linked hematology platforms in acute care settings. |
| Quest Diagnostics | Aug-25 | Quest Diagnostics completed the acquisition of select clinical testing assets from Fresenius Medical Care’s Spectra Laboratories. The transaction enhances Quest’s chronic disease testing capabilities and expands its clinical diagnostics portfolio, supporting broader service integration across kidney disease and inflammation-related testing segments. |
| Siemens Healthineers | Jul-25 | Siemens Healthineers received the My Green Lab ACT Ecolabel certification for more than 150 immunoassay and clinical chemistry reagents, including its Atellica portfolio. This certification reflects improvements in sustainable reagent manufacturing practices, reinforcing the company’s positioning in environmentally optimized diagnostic production and laboratory workflow solutions. |
| Siemens Healthcare Diagnostics Products GmbH | Nov-23 | Siemens received FDA 510(k) clearance for its CardioPhase high-sensitivity C-reactive protein (hs-CRP) test. The approval enables U.S. commercialization of a quantitative CRP assay for cardiovascular risk assessment, strengthening Siemens’ immunoassay portfolio and expanding clinical utility in inflammation and cardiac risk diagnostics. |
| Qlife Holding AB | Jan-23 | Qlife launched the Egoo CRP capsule in Sweden as a soft introduction to its home testing platform. The product enables non-professional biomarker testing and represents an early step toward broader CE-marked clinical use, expanding access to CRP-based inflammation monitoring in decentralized and home-care settings. |
| LumiraDx | Jan-22 | LumiraDx achieved CE marking for its C-reactive protein (CRP) test, enabling commercialization of a portable microfluidic immunoassay system. The test delivers rapid quantitative results and strengthens the company’s point-of-care diagnostics portfolio, supporting faster inflammation assessment in decentralized healthcare environments. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
C-reactive Protein Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood/Serum, Plasma, Whole Blood, Other Clinical Samples |
| Purchasing Model | Direct Procurement, Distributor-Mediated Procurement, Group Purchasing Organization (GPO) Procurement, Contract-Based Procurement |
| Payer Type | Public Health Insurance, Private Health Insurance, Self-Pay, Employer-Sponsored Healthcare |
C-reactive Protein Testing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Inflammatory Disease Diagnostic Pathway Analysis |
|
| Point-of-Care Testing Adoption Strategies |
|
| Diagnostic Testing Reimbursement Landscape |
|
Need a different cut of the data?
Request Custom ResearchHow large is the C-reactive protein testing market?
How will the C-reactive protein testing industry grow in terms of size and CAGR by 2036?
How is point-of-care testing changing procurement priorities in the C-reactive protein testing market?
What is driving recurring demand for C-reactive protein testing across healthcare systems?
Why does hs-CRP lead the C-reactive protein testing market?
Which assay type is growing the fastest in the C-reactive protein testing market?
Why does North America lead the C-reactive protein testing market?
What is driving rapid growth in the Asia Pacific C-reactive protein testing market?
Who holds a significant market share in the C-reactive protein testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization